Clinical Trial Update: Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating Penostatin, Rituximab, Ontak, and allogeneic NK cells in refractory lymphoid malignancies has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• Allogeneic Natural Killer (NK) Cells
• ONTAK (denileukin diftitox)
• Penostatin
• Rituximab (rituximab)

Snippet

Sponsor: Masonic Cancer Center, University of Minnesota | Conditions: Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED | Results posted: 2017-05-18